Welcome to our dedicated page for Medifast SEC filings (Ticker: MED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medifast’s weight-loss meal plans may look simple on the surface, but its SEC disclosures tell a deeper story about coach networks, inventory swings, and regulatory risk. If you have ever asked “Medifast SEC filings explained simply” or “Where can I track Medifast insider trading Form 4 transactions,” this page is built for you.
Stock Titan’s AI reads every Medifast filing the moment it lands on EDGAR. Need the Medifast quarterly earnings report 10-Q filing without combing through footnotes? Our AI-powered summaries surface margin changes, coach counts, and deferred revenue in seconds. Looking for Medifast executive stock transactions Form 4? Real-time alerts flag each sale or purchase so you never miss a signal.
Here’s how each form connects to Medifast’s business:
- 10-K annual report: Coach retention rates, segment revenue, and risk factors—see the Medifast annual report 10-K simplified by our AI.
- 10-Q: Quarter-over-quarter inventory and advertising spend—perfect for quick Medifast earnings report filing analysis.
- 8-K material events: Product recalls or leadership changes? Find Medifast 8-K material events explained in plain English.
- Form 4: Monitor Medifast Form 4 insider transactions real-time and spot buying before new program launches.
- DEF 14A proxy: Review Medifast proxy statement executive compensation to see how management pay aligns with coach growth.
Whether you’re comparing GLP-1 strategy disclosures or understanding Medifast SEC documents with AI, our platform converts dense filings into clear, actionable insights—updated the moment Medifast hits “submit.”
Medifast, Inc. reported several leadership and compensation changes. Anthony Tyree, Chief Business Operations Officer and a named executive officer, will leave the company effective December 31, 2025. Under a separation agreement and the executive severance policy, he will receive a lump-sum payment equal to one year of salary of $415,873 plus a target bonus of $291,111, his 2025 bonus based on actual performance, prorated vesting of restricted and performance share units through December 31, 2025, continued welfare plan coverage at active employee rates through December 31, 2026 if he elects COBRA, and up to six months of outplacement assistance.
Effective January 5, 2026, Nicholas Johnson is promoted from Chief Field Operations Officer to President of Medifast, adding responsibility for enterprise marketing, scientific and clinical affairs, product development, and consumable product and plan management. On the same date, CEO and Chairman Daniel Chard announced a planned transition to non-executive Chairman effective June 1, 2026. His letter agreement reduces his annual salary from $1,000,000 to $800,000, target bonus from 115% to 100%, and target long-term incentive from $4,600,000 to $2,400,000, with prorated 2026 incentives and continued vesting of existing equity while serving as non-executive Chairman.
Medifast (MED): G1 Execution Services, Susquehanna Fundamental Investments, and Susquehanna Securities filed an amended Schedule 13G reporting beneficial ownership of 654,945 shares of common stock, equal to 6.0% of the class as of 09/30/2025.
The filing notes that Susquehanna Securities’ reported holdings include options to buy 613,400 shares. The reporting persons indicate shared voting and dispositive power over 654,945 shares, with certain sole powers listed individually on their cover pages. Medifast had 10,991,064 shares outstanding as of July 28, 2025, per the company’s Form 10‑Q.
The group certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Charles Schwab Investment Management, Inc. filed a Schedule 13G disclosing a passive stake in Medifast, Inc.
The filing reports 595,211 shares of common stock, representing 5.41% of the class, tied to the event date 09/30/2025. The firm holds sole voting power over 595,211 shares and sole dispositive power over 595,211 shares, with no shared voting or dispositive power.
The reporting person is classified as an investment adviser (IA) and certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Medifast (MED) reported a weak quarter as demand softened. Revenue was $89.4 million, down 36.2% year over year, and the company posted a net loss of $2.3 million ($0.21 per diluted share) versus a profit a year ago. Nine‑month revenue was $310.7 million, down 35.7%, with a net loss of $0.6 million.
Results reflect a sharp decline in the OPTAVIA coach network and productivity. Active earning coaches fell to 19,500 from 30,000, and average revenue per active coach slipped to $4,585. Gross margin narrowed to 69.5% (down 590 bps), pressured by lower volume leverage and a reserve tied to reformulating the Essential product line. SG&A fell in dollars but remained elevated at 74.1% of revenue.
Liquidity remains solid: cash, cash equivalents and investments were $173.5 million, with working capital of $161.1 million. Operating cash flow was $12.1 million for the nine months. The company exited its LifeMD equity position earlier in the year, contributing to $7.2 million of other income year‑to‑date. Shares outstanding were 10,991,273 as of October 27, 2025.
Medifast, Inc. (MED) reported an administrative update via Form 8-K. The company announced it issued a press release covering earnings for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished, not filed, meaning it is not subject to Section 18 of the Exchange Act and will not be incorporated into other filings unless specifically referenced. No financial figures are included in this notice; detailed results are contained in the attached press release.
Medifast Schedule 13G filing summary The reporting entities—G1 Execution Services, LLC; Susquehanna Fundamental Investments, LLC; and Susquehanna Securities, LLC—report aggregate beneficial ownership of 785,606 shares, representing 7.2% of Medifast's outstanding common stock based on 10,938,000 shares outstanding as of June 30, 2025. The filing expressly states that the Susquehanna Securities total includes options to acquire 695,200 shares.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control. The report is executed and signed on August 13, 2025. No additional transactions, plans, or intentions are disclosed in this statement.
Medifast Director Xian Ming received two grants of Restricted Stock Units (RSUs) on June 25, 2025:
- 11,167.65 cash-settled RSUs as part of director compensation, vesting fully on June 25, 2026
- 6,013.35 additional RSUs valued at $13.39 per share (based on 20-day moving average), elected in lieu of cash compensation
Both RSU grants will be payable in cash upon Ming's termination of service as director. Following these transactions, Ming beneficially owns 26,129.568 RSUs from the first grant and 32,142.918 RSUs from the second grant. The RSUs were granted under Medifast's Director's Deferred Compensation Plan and the Amended and Restated 2012 Share Incentive Plan.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
